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1. INTRODUCTION 
Traditionally, drug delivery systems have focused on 
constant/sustained drug output with the objective of 
minimizing peaks and valleys of drug concentrations in 
the body to optimize drug efficacy and to reduce adverse 
effects. Diseases where a constant drug levels are not 
preferred, but needs a pulse of therapeutic concentration 
in a periodic manner acts as a push for the development 
of “Chronopharmaceutical Drug Delivery Systems” 1-2. 
The Montelukast Sodium is Leukotriene receptor 
antagonist used for the maintenance treatment of asthma, 
chronic asthma attacks and to relive symptoms of 
seasonal allergies.  
Asthma is chronic inflammatory disease of the airways, 
characterized by hyper responsiveness to variety of 
stimuli. The role of circadian rhythm in the photogenesis 
and treatment of asthma indicates that airway resistance 
increases progressively at night in asthmatic patient. 
Circadian changes are seen in normal lung function, 
which reaches in low point in the early morning hours. 
The worsening of asthma at night, commonly referred to 
as Nocturnal Asthma (NA). A drug delivery system 
administered at bedtime but releasing drug during 
morning hours would be ideal in this case. Nocturnal 
Asthma is variable exacerbation of underlying asthma 
condition associated with increase in symptoms, need 
for medication, airway responsiveness, and/or worsening 
of lung function
4
.Press coated tablets (PCTs) gained 
wide interest ‘claiming some advantages over regular 
and (pan-) coated tablets, such as to protect hygroscopic, 
light-sensitive or oxygen-labile drugs from 
environmental-atmospheric ill effects or decomposition 
of acid-labile drugs by gastric fluids; to separate 
incompatible drugs from each other; to achieve a 
sustained release in that the drug in the core is embedded 
in waxes or fats constituting a depot; to protect the 
gastric mucosa from irritation by certain drugs by using 
enteric coating material in the outer  press-coating 
granules; or to achieve intermittent release by 
incorporating one portion of drug in the core and the 
other in the coat, separated by a film-coat or a second 
press-coat drawbacks of the press-coating technique are 
the multistep processes involved, and the requirement 
for reliable and reproducible central positioning of the 
core tablet within press-coated tablet (PCT)
5-8
. The aim 
of the study was to develop and physico-chemically 
characterize pulsatile delivery tablet of Montelukast 
using different polymers. Montelukast has a biological 
half-life of about 2.5-5.5 hrs and 64 % bioavailability. 
Development of pulse release formulation of 
Montelukast can be advantageous, that can provide 
specific lag time and increase compliancy of the dosage 
form towards patient’s side. Asthma peak is more in 
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early morning so it is not feasible to take tablet in 
midnight so pulsatile delivery is preferred one because 
this type of tablet should be taken after dinner which 
deliver drug immediately after a specified lag time about 
4-5hrs. So drug may available (right time, right site) in 
blood circulation about 3 o’clock so it is available to 
protect from early morning asthma due to its 4-6 hrs. of 
half-life
3
. 
So development of formulation consisted of a rapidly 
disintegrating core tablet press coated by a barrier 
layer consisting of varying concentrations of Xanthan 
Gum, Polyox303, Ethyl cellulose and 
Hydroxypropylmethyl cellulose. Ethylcellulose and 
hydrophilic polymers are used as a rate controlling 
polymer to achieve desired lag time. 
MATERIALS AND METHODS 
Drug Montelukast Sodium was obtained as gift sample 
from Shreya pharmaceutical ltd. Chikalthana, 
Aurangabad, Maharashtra, India.Poloxomer-188, 
Poloxomer-407, Crosscarmalose sodium, 
Microcrystalline Cellulose, Sodium Starch Glycolate, 
Lactose, HPMC, Ethyl Cellulose, Xanthan Gum, Polyox 
were obtained from Research Lab Fine Chem.  
Preparation of core tablets:  
The inner-core tablets were prepared using direct 
compression to perform various release kinetics, 
depending upon the release mechanism involved. The 
composition of different formulations were prepared 
applying design expert software factorial design in 
which varying amounts of superdisintegrants, type of 
superdisintegrant, surfactant and diluents. Drug and the 
Excipients were homogeneously blended and 
subsequently compressed into tablet (6 mm Punch) using 
12 station multi tooling rotary tablet punching machine 
The levels for the formulation design were as given in 
table 1. 
 
Table 1Formulation variables and their levels for core tablet optimization. 
 
Table 2 summarizes the experimental runs, their factor combinations and the translation of the coded levels to the 
experimental units used in the study. 
Table 2: Factor combinations as per the chosen experimental design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formulation of Press coated tablet: 
Powder blend for press-coated tablet was prepared by 
dry blending together different compositions of the Ethyl 
cellulose, HPMC, Polyox WSR301, and Xanthan gum as 
shown in Table 3. These excipients were dry blended in 
different weight compositions using surface response 
design in order to get suitable polymer composition. 
This composition was dry blended until uniformly 
blended mixture was obtained. This mixture was then 
used for the preparation of press – coated tablet using 
direct compression method (10mm punch). 
Level X1-Concentration 
of Surfactant (mg) 
X2-Concentration of  
superdisintegrants (%) 
X3-  Type of 
Surfactant 
X4-  Type of 
superdisintegrants 
X5-Type of 
Diluent 
-1 -1 -1 Poloxamer 407 (-1) CCS(-1) MCC(-1) 
+1 1 1 Poloxamer 188 (1) SSG(1) Lactose(1) 
Dependent Variable Y1- Drug release in 30minutes 
Y2-Disintegration Time (DT) 
Batch code X1 X2 X3 X4 X5 
1 -1.000 -0.800 -1 -1 -1 
2 1.000 -1.000 -1 1 1 
3 0.210 -0.040 -1 -1 -1 
4 -1.000 1.000 -1 -1 1 
5 0.160 1.000 1 -1 -1 
6 0.910 0.250 -1 1 1 
7 -1.000 -1.000 1 1 1 
8 1.000 1.000 1 1 1 
9 -1.000 -1.000 1 1 1 
10 0.210 -0.040 -1 1 -1 
11 -1.000 1.000 -1 1 -1 
12 1.000 -1.000 1 -1 -1 
13 0.160 1.000 1 -1 -1 
14 1.000 -1.000 1 -1 -1 
15 0.910 0.250 -1 -1 1 
16 -0.500 0.500 1 1 1 
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Table 3: Formulation variables for press coated tablet optimization 
Level 
X1-Concentration  of Ethyl 
Cellulose 
X2-Concentration of 
polymer 
X3-Type of Polymers 
-1 0 50 HPMC(10000) 
0 75 100 Xanthan gum(01000) 
+1 150 150 Polyox (00100) 
HPMC+ Polyox(-1-1-1-1-1) 
HPMC+ Xanthan gum(00001) 
Polyox+ Xanthan gum(00010) 
Dependant Variables: Y- Lag Time 
 
Table 4: Formulation of Press coated tablet 
Formulation Factor-1 Concentrationof 
polymer 
Factor-2 Concentration of 
Ethyl cellulose 
Factor-3 Types of Polymer 
1 -0.8 -0.83481 { 0 0 1 0 0 } 
2 -0.07 -0.06 { 0 0 1 0 0 } 
3 -1 0 { 0 0 0 1 0 } 
4 0.971953 -0.3 { 0 0 1 0 0 } 
5 0.960118 -0.35 { 0 1 0 0 0 } 
6 0 1 { 0 0 0 1 0 } 
7 -1 -1 { -1 -1 -1 -1 -1 } 
8 -0.55 0.56 { -1 -1 -1 -1 -1 } 
9 -0.83 -0.82 { 0 1 0 0 0 } 
10 0.53 -0.54863 { -1 -1 -1 -1 -1 } 
11 -1 1 { 0 0 0 0 1 } 
12 0 -1 { 0 0 0 1 0 } 
13 0.53 -0.54863 { -1 -1 -1 -1 -1 } 
14 -0.4 0.96767 { 0 0 1 0 0 } 
15 -0.55 -0.56 { 0 0 0 0 1 } 
16 0.95 -0.44 { 1 0 0 0 0 } 
17 -1 0.19 { 0 1 0 0 0 } 
18 0.71 0.84 { 0 1 0 0 0 } 
19 0.56 0.55 { 0 0 0 0 1 } 
20 1 1 { -1 -1 -1 -1 -1 } 
21 1 0.623881 { 1 0 0 0 0 } 
22 1 0 { 0 0 0 1 0 } 
23 0.56 0.55 { 0 0 0 0 1 } 
24 -0.36 0.98 { 0 1 0 0 0 } 
25 0.17 -1 { 0 1 0 0 0 } 
26 -0.55 -0.56 { 0 0 0 0 1 } 
27 -0.28 0.95 { 1 0 0 0 0 } 
28 -0.55 0.56 { -1 -1 -1 -1 -1 } 
29 1 -1 { 0 0 0 0 1 } 
30 -0.86 -0.79 { 1 0 0 0 0 } 
31 0.971953 -0.3 { 0 0 1 0 0 } 
 
Evaluation of press coated tablets 
Core tablets and Press Coated Pulsatile Tablets were 
evaluated for following parameters as per their 
pharmacopoeial procedures. 
Hardness test: It was determined using Monsanto 
hardness tester
9-11
. 
Friability test: Ten tablets were initially weighed and 
transferred into Roche friabilator. The friabilator was 
operated at 25 rpm for 4 minutes
9-11
. 
Weight variation test: Ten tablets were selected 
randomly from each formulation and weighed 
individually to check for weight variation
9-,11
. 
In vitro drug release studies: 
(A) Core Tablets 
The in vitro drug release from core tablets was carried 
out using USP paddle apparatus at 50 rpm and 37±0.5ºC. 
Phosphate buffer (pH 6.8) was used as the dissolution 
medium. The samples were withdrawn at regular 
intervals and analyzed by UV spectrophotometer at 
225nm for the presence of the drug. Dissolution tests 
were performed in triplicate
9-11
. 
Chaudhary et al                                      Journal of Drug Delivery & Therapeutics. 2016; 6(1):25-33 28 
© 2011-15, JDDT. All Rights Reserved                                                   ISSN: 2250-1177                                             CODEN (USA): JDDTAO 
(B) Press Coated Pulsatile Tablets 
The in vitro drug release from coated tablets was carried 
out using USP paddle apparatus at 50 rpm. HCl (0.1 N) 
and phosphate buffer (pH 6.8) were used as the 
dissolution medium. Initially tablets were subjected to 
dissolution in 0.1 HCl for 2h and after that media were 
changed to phosphate buffer (pH 6.8). The samples were 
withdrawn at regular intervals and analyzed by UV 
spectrophotometer at 225 nm for the presence of the 
drug. Dissolution tests were performed in triplicate. 
RESULT & DISCUSSION: 
Compatibility Studies 
In order to investigate the possible interactions between 
Montelukast Sodium and polymers and/or diluents, FT-
IR of Drug were carried out by using FTIR 
spectrophotometer (FTIR-8400S)as shown in Fig.1a,and 
b. FT-IR results proved that the drug was found to be 
compatible with excipients as wave numbers are almost 
similar for pure drug and also drug excipients mixture.
 
 
Figure 1a: IR spectrum of the Montelukast sodium Drug 
 
Figure1b: IR spectrum of A) Drug B) Drug+Sodium Starch Glycolate C) Drug+Cross Camallose Sodium D) 
Drug+Lactose E) Drug+Microcrystalline Cellulose. 
 
Precompression Parameters of Core Tablet Powder Blend 
Bulk density, tapped density, Hausner’s ratio and carr’s index given  in the Table5.The angle of repose (θ) for all the 
formulation ranged from 19 to 25° indicating good flow properties. The result of compressibility index was between 12 
to 16, which indicates good flow properties & for Hausners ratio was near/less about 1.2 also supported the results of 
free flowing. 
Postcompression Parameters of Core Tablets 
The tablet hardness, friability, weight variation of all tablet formulations were found to be satisfactory and reproducible 
as observed from the data in Table 6. The hardness of all the tablets was between 3 to 5kg/cm
2
.  In the present study, 
the loss in total weight in friability test was in the range of 0.77 to 0.91% that indicates, the percentage friability for all 
the  formulations  was  found  below  1%  indicating  that  friability  (%)  is  within  the  acceptable limits. In weight 
variation test, the pharmacopoeia limit for the percentage deviation for tablets weighing more than50 mg is ±7.5%.  The  
average  percentage  deviation  of  all  tablet formulations was  found to be within limit, and hence all formulations 
passed the test for uniformity  of  weight  as  per  official  requirement.  
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Table5: Evaluation of directly compressible blends of core tablet 
 
Table 6: Evaluation of Formulations of rapid release core tablet 
 Hardness(kg/c
2
) 
(n=3) 
Thickness(mm) 
(n=3) 
Diameter 
(mm) 
Weight 
variation(%)(n=20) 
Disintegration 
time (Sec.) 
Friability 
(%) 
(n=10) 
F1 3.5±0.50 2.64±0.012 6.01±0.015 101±0.67 150 0.78 
F2 4± 0.50 2.54±0.005 6.00±0.010 100±0.54 21 0.66 
F3 5±0.50 2.60±0.010 6.02±0.007 102±0.66 180 0.62 
F4 3±0.50 2.52±0.014 6.00±0.015 100±0.57 18 0.87 
F5 3±0.50 2.65±0.009 6.01±0.009 100±0.88 105 0.85 
F6 3±0.50 2.55±0.010 6.01±0.015 101±0.85 22 0.80 
F7 4±0.50 2.57±0.012 6.03±0.017 99±1.15 24 0.78 
F8 5±0.50 2.39±0.019 6.02±0.013 101±0.75 25 0.67 
F9 4±0.50 2.5±0.020 6.02±0.012 98±1.3 24 0.71 
F10 3±0.50 2.59±0.018 6.00±0.014 99±1.1 180 0.69 
F11 3±0.50 2.69±0.019 6.01±0.009 99±1.2 210 0.81 
F12 4±0.50 2.60±0.017 6.02±0.015 103±0.75 255 0.77 
F13 5±0.50 2.504±18 6.03±0.015 101±0.60 105 0.62 
F14 4±0.50 2.58±0.015 6.01±0.008 103±0.54 255 0.70 
F15 4±0.50 2.61±0.012 6.03±0.018 103±0.56 22 0.82 
F16 5±0.50 2.67±0.013 6.02±0.015 99±1.2 31 0.84 
 
 
In-Vitro Drug Release of core tablet 
For preparation of immediate release core tablets 
different superdisintegrants were used. In that 
Poloxomer-407 containing formulation shows 
immediate & more release compared to other 
formulations. F4 formulation showed 95.49% drug 
release in 30 minas observed in Figure 2a.The result 
shows that lactose with superdisentegrants shows good 
disintegration & dissolution properties as Lactose is 
highly water soluble & along with superdisintegrants the 
release was very fast. Whereas in spray dried mucilage-
lactose, might have increased the viscosity &could have 
acted as barrier for diffusion & faster dissolution. 
Formulations Bulk 
Density(g/cm
3
) 
Tapped 
Density(g/cm
3
) 
Angle of 
Repose(
0
 ) 
Carrs index 
(%) 
Hausners ratio 
(HR) 
F1 0.48 0.50 25.066 19.0 1.19 
F2 0.55 0.60 21.65 16.6 1.20 
F3 0.45 0.55 19.50 10.0 1.11 
F4 0.55 0.66 21.03 16.6 1.20 
F5 0.49 0.55 18.25 23.63 1.30 
F6 0.50 0.60 19.9 16.6 1.20 
F7 0.62 0.65 21.41 4.6 1.02 
F8 0.50 0.55 19.69 18.0 1.21 
F9 0.62 0.65 18.41 4.6 1.02 
F10 0.45 0.48 22.50 10.0 1.11 
F11 0.50 0.60 21.74 16.6 1.20 
F12 0.45 0.50 19.13 18.0 1.21 
F13 0.50 0.55 18.25 23.63 1.30 
F14 0.45 0.50 22.13 18.0 1.21 
F15 0.50 0.60 25.90 16.6 1.20 
F16 0.45 0.50 27.74 18.0 1.21 
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Figure 2a: Percent Drug Release of core tablets 
 
The response surface graph  figure 2b shows that as the 
conc. of superdisentigrants and conc. of surfactant 
increases % drug release decreased. While with increase 
in superdisintegrant and decrease in surfactant conc 
increases the drug release.This might be due to high 
conc of surfactant drug may be entrapped in surfactant 
micelles. 
 
Figure 2b: Effect of superdisintegrants and surfactant on drug Release  
 
Postcompression Parameters of Press-Coated Tablets 
The tablet hardness, friability, weight variation of all 
tablet formulations were found to be satisfactory and 
reproducible as observed from the data in Table 7.The 
hardness of all the tablets was between7 and 8kg/cm
2
.  
In the present study, the loss in total weight in friability 
test was in the range of 0.66 to 0.99% that indicates, the 
percentage friability for all the  formulations  was  found  
below  1%  indicating  that  friability  (%)  is  within  the  
acceptable limits. In a weight variation test, the 
pharmacopoeia limit for the percentage deviation for 
tablets weighing more than100mg is ±5%.  The  average  
percentage  deviation  of  all  tablet formulations was  
found to be within limit, and hence all formulations 
passed the test for uniformity  of  weight  as  per  official  
requirement. 
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Table 7: Post-Compression Parameters for Press-Coated Tablets 
Formulations Hardness 
(Kg/cm
2
) 
(n=3) 
Thickness 
(mm)(n=3) 
Diameter 
(mm)(n=3) 
Weight 
Variation (%) 
(n=20) 
Friability (%) 
(n=10) 
F1 7±0.40 6.17±0.027 10.01±0.01 122.39±1.2 0.92 
F2 7.5±0.27 5.89±0.15 10.00±0.02 217±1.4 0.86 
F3 7±0.63 5.93±0.26 10.01±0.02 175±1.1 0.73 
F4 7±0.28 6.09±0.27 10.02±0.02 251.1±1.1 0.77 
F5 7.5±0.13 5.97±0.15 10.01±0.01 246.17±1.7 0.73 
F6 8±0.45 5.95±0.26 10.00±0.02 300±2 0.68 
F7 8±0.29 6.13±0.17 10.00±0.002 100±1.5 0.93 
F8 7±0.28 6.02±0.15 10.01±0.01 239.5±1.4 0.88 
F9 7±0.50 5.89±0.15 10.01±0.01 122±1.1 0.69 
F10 7±0.40 5.93±0.26 10.00±0.02 210.35±1.1 0.82 
F11 7.5±0.27 6.09±0.27 10.00±0.002 250±1.1 0.92 
F12 7±0.63 5.97±0.15 10.01±0.01 150±1.4 0.77 
F13 7±0.40 5.93±0.26 10.00±0.02 210.35±1.1 0.82 
F14 7.5±0.13 6.13±0.17 10.01±0.02 277.58±1.2 0.81 
F15 8±0.45 6.02±0.15 10.02±0.02 155.5±1.2 0.92 
F16 8±0.29 5.97±0.15 10.01±0.01 239.5±1.3 0.97 
F17 7±0.28 6.09±0.27 10.00±0.02 189.25±1.3 0.96 
F18 7±0.50 5.97±0.15 10.00±0.002 323.5±1.1 0.72 
F19 7±0.40 5.95±0.26 10.01±0.01 294.25±1.6 0.67 
F20 7.5±0.27 6.13±0.17 10.01±0.01 350±1.8 0.69 
F21 7±0.63 6.02±0.15 10.00±0.02 321.79±1.4 0.79 
F22 7±0.28 5.93±0.26 10.00±0.002 275±1.1 0.88 
F23 7±0.40 5.95±0.26 10.01±0.01 294.25±1.6 0.67 
F24 8±0.45 5.97±0.15 10.00±0.002 280±2.0 0.69 
F25 8±0.29 5.95±0.26 10.01±0.01 158.5±1.9 0.92 
F26 8±0.45 6.02±0.15 10.02±0.02 155.5±1.2 0.92 
F27 7±0.50 6.02±0.15 10.01±0.02 282.25±1.0 0.90 
F28 7±0.28 6.02±0.15 10.01±0.01 239.5±1.4 0.88 
F29 7.5±0.27 5.93±0.26 10.01±0.01 200±1.5 0.86 
F30 7±0.63 6.09±0.27 10.00±0.02 22.75±1.4 0.87 
F31 7±0.28 5.95±0.26 10.00±0.002 251.1±1.1 0.99 
 
The percent release of drug for all tablet formulations was found to be satisfactory and reproducible. 
 
 
Figure 3a: Percent drug release of coated formulations % Drug Release of coated formulations (Ethyl Cellulose 
and Polyox) 
% 
Release 
Time(Hrs.) 
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Figure 3b: Percent drug release of coated formulations (Ethyl Cellulose and Xanthan gum) 
 
 
Figure 3c: Percent drug release of coated formulations (Ethyl Cellulose and HPMC) 
 
Figure 3d: Percentdrug release of coated formulations (Ethyl Cellulose and Polyox+ Xanthan gum) 
 
 
Figure 3e: Percent drug release of coated formulations (Ethyl Cellulose and Xanthan gum+ HPMC) 
% Release 
Time(Hrs.) 
Time(Hrs.) 
% Release 
% Release 
Time(Hrs.) 
% 
Release 
Time(Hrs.) 
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-  
Figure 3f: Percent drug release of coated formulations (Ethyl Cellulose and HPMC+Polyox) 
Drug Release of coated formulations:- 
Lag time is the important criteria to deliver drug. In 
following formulations different polymers in different 
concentration were used.The coated tablet formulation 
consisting of ethyl cellulose and Polyox, ethyl cellulose 
and xanthum gum ,ethyl cellulose and HPMC achieved 
maximum 140 minutes,175 minutes and 165minutes 
maximum lag time respectively( figure (3a,3b,3c)).  
While the combination formulation consisting of ethyl 
cellulose, Polyox and xanthum gum, ethyl cellulose, 
xanthum gum and HPMC and  ethyl cellulose, HPMC 
and Polyox achieved maximum 210 minutes,170 
minutes and 165 minutes Lag time respectively(Figure 
3d,,3e,3f)). In this F12 formulation containing Xanthan 
gum, Polyox and ethyl cellulose combination showed 
the exact sigmoid curve and maximum lag time. Ethyl 
cellulose is hydrophobic in nature and Xanthan gum as 
per literature is known to prolong the drug release when 
it is combined with Polyox a water soluble high 
molecular weight resin the lag time is prolong for longer 
period of time.  
CONCLUSION 
Chronopharmaceutical Drug delivery formulations were 
prepared by direct compression press coating using 
Response Surface Methodology with polymers as 
Xanthan gum, Polyox, HPMC & Ethyl Cellulose alone 
and in combination. Polyox having a property of fast 
hydration & swelling useful for maintaining lag time. 
Xanthan gum has more viscosity on coming in contact 
with solvent and ethyl cellulose a hydrophobic polymer. 
So, combinations of these polymers give better lag time. 
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